Even though regulatory bodies like the EMA and FDA cannot work in tandem with industry and academia, they do share a common goal: to develop and launch new drugs that improve society's wellbeing.

TI Pharma brings all stakeholders to the same table. It acts as a neutral platform where common ground can be created and conflicting interests can be mediated, jointly working towards an improved and innovation-friendly regulatory framework.

TI Pharma enables several such partnerships, including:

  • Escher: An international, multi-stakeholder platform for regulatory sciences activities to optimize guidance, policy and regulations in the development of medicines and medical technology
  • Non-Biological Complex Drugs Working Group: Working group investigating science-based approval and post-approval standards for non-biological complex drugs

“TI Pharma's partnerships result in a synergy that really drives the science further than the individual parties could achieve working alone.”

Jan Raaijmakers
Past VP External Scientific Collaborations GSK Europe
Chair TI Pharma Board of Directors

Share this page: